In a recent paper, researchers recommended prompt screening methods and management strategies for comorbidities that occur commonly in patients with COPD.

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Long-term oxygen therapy (LTOT) is linked to reduced exacerbations and hospitalizations in COPD, ILD, and pulmonary hypertension.

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

The approval tees GSK up to challenge Sanofi and Regeneron, which in September 2024 won the first biologic approval for COPD ...

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

The U.S. Food and Drug Administration has approved GSK plc (NYSE: GSK )’s asthma medication, Nucala, for expanded use in ...

Remember, COPD treatment is a long-term journey with many facets, and each case is different. For example, you might be great at keeping up with your medications and doctor appointments but not so ...

In 2024, drugmakers delivered breakthrough treatments in conditions that had ... while Verona’s dual-action treatment for COPD offers a breakthrough in maintenance therapy that will help some ...